drugset / Trial / NCT03915860

Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris

NCT03915860

Phase 3 Completed 47 enrolled Galderma R&D
NaSingle-groupOpen-labelTreatment

Summary

Participant Reported Outcomes with use of Trifarotene 50 μg/g Cream in participants with Moderate Facial and Truncal Acne Vulgaris

Timeline

Start
2019-03-27
Primary completion
2019-12-23
Completion
2019-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Trifarotene Small molecule 50 unknown Topical

Indications